AI has made building intelligent data applications easier than ever—but in global pharma, ease of implementation does not equal trust. Across regions, the same drug, KPI, or business concept carries different identities, definitions, and regulatory meanings. This session explores why naïve AI adoption can produce technically correct yet semantically unsafe insights.
Using real‑world pharma scenarios—global drug identity resolution, cross‑regional market share, and retroactive data corrections—we show where AI falls short and why modern data engineering is critical. The talk highlights how semantic models, metadata‑driven governance, time‑aware lineage, and federated architectures enable trustworthy AI at scale.
The key message: AI sits on top of semantic infrastructure. As AI commoditizes implementation, data engineering’s role evolves from moving data to preserving enterprise meaning, context, and trust across markets and time.